Clinical trials: Double-blind Randomized Controlled Study
Seborrheic Dermatitis
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.
- Trial name
- NCT01703793
- Testing
- Test Product 49778, Test Product 10156
- Where
- 22 sites in United States
- Volunteers
- 240 people
- Sponsor
- Medicis Global Service Corporation
Acne Vulgaris
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
- Trial name
- NCT04797793
- Testing
- Adapalene Gel 0.1%, Differin® Gel (Adapalene 0.1%, Galderma)
- Where
- United States
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to…
- Trial name
- NCT05327114
- Testing
- Nipocalimab
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Multiple Ascending Dose Study for LCB01-0371
Primary To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral dose in healthy male subjects To investigate the…
- Trial name
- NCT01842516
- Testing
- LCB01-0371 800mg, LCB01-0371 1200mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LigaChem Biosciences, Inc.
Atopic Dermatitis
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01548404
- Testing
- Dupilumab
- Where
- 21 sites in Czechia, France and 3 more
- Volunteers
- 109 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.
- Trial name
- NCT00557284
- Testing
- Montelukast
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- 1st Allergy & Clinical Research Center
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Hyperkalemia
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of…
- Trial name
- HARMONIZE GL (NCT02875834)
- Testing
- Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g
- Where
- 45 sites in Japan, Russia and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Obesity, Metabolic Syndrome
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.
- Trial name
- NCT05891834
- Testing
- INV-202
- Where
- 24 sites in Canada
- Volunteers
- 243 people
- Sponsor
- Inversago Pharma Inc.
Hypercholesterolemia
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
- Trial name
- NCT04358432
- Testing
- AK102, Statins and/or Ezetimibe
- Where
- 2 sites in China
- Volunteers
- 262 people
- Sponsor
- Akeso
Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- ANCHOR (NCT07159763)
- Testing
- MK-1406
- Where
- 185 sites in United States, Argentina and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Corona Virus Infection
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019…
- Trial name
- NCT04469621
- Testing
- SAR443122
- Where
- 10 sites in Argentina, Brazil and 3 more
- Volunteers
- 68 people
- Sponsor
- Sanofi
Oral Lichen Planus
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
A phase 2 randomized, placebo-controlled, double-blind trial of a two week course of curcuminoids in oral lichen planus will be conducted.
- Trial name
- NCT00525421
- Testing
- Curcuminoids
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nita Chainani Wu
High Oxidation Stress, Oxidized LDL Level
Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status
This is a Randomized, Double-blind, Placebo-controlled, Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status.
- Trial name
- NCT01551706
- Testing
- ENI Patented Whole Grape Extract
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Ethical Naturals, Inc.
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Dyslipidemia
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effects of RS-C1001 tablets in Chinese healthy subjects. This study will consist of two parts (Parts A and B).
- Trial name
- NCT06669429
- Testing
- RS-C1001
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Alpha 1-Antitrypsin Deficiency, Emphysema
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
- Trial name
- ELEVAATE (NCT05856331)
- Testing
- SAR447537, Zemaira
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
Coronary Heart Disease
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS).
- Trial name
- NCT01323153
- Testing
- dalcetrapib
- Where
- 33 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Clostridioides Difficile Infection
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response…
- Trial name
- Ri-CoDIFy 1 (NCT03595553)
- Testing
- Ridinilazole, Vancomycin
- Where
- 149 sites in United States, Argentina and 12 more
- Volunteers
- 759 people
- Sponsor
- Summit Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.